| Literature DB >> 36060908 |
Saeed Abdi1, Sara Ataei2, Maede Abroon3, Pantea Majma Sanaye3, Mohammad Abbasinazari4, Amir Farrokhian4.
Abstract
Antibiotic-resistant Helicobacter pylori isolates have become a global concern. The standard triple or quadruple therapies have recently become the most effective protocol for eradicating H. pylori in the gastrointestinal tract. There is evidence regarding the impact of different complementary or dietary supplements on H. pylori eradication. This review article intended to search electronic bibliographic databases for any clinical studies that evaluated the use of any herbal or dietary supplements to eradicate H. pylori up to June 2021. A total of 20 human studies met our criteria and were reviewed. Although some herbal medicines have shown their efficacy and safety in eradicating H. pylori in different clinical trials, more randomized blind, placebo-controlled human trials with a large sample size must be performed to extend our knowledge.Entities:
Keywords: Clinical Trials; Gastrointestinal Disorders; Herbal Medicines; Medical Databases; Nutraceuticals
Year: 2022 PMID: 36060908 PMCID: PMC9420233 DOI: 10.5812/ijpr-127030
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.962
Figure 1.Search strategy
Summary of Human Studies on the Effect of Complementary and Dietary Supplements on Helicobacter pylori Eradication
| Active Component/ Dose/ Duration | First Author (Year/ Country) (Reference Number) | Putative Anti- | Type of Studies | Number of Patients | Intervention Group | Concurrent Antibiotics Eradication Regimen | Effect |
|---|---|---|---|---|---|---|---|
|
| Boyanova et al. (2015/ Bulgaria) ( | Polyphenolic for inhibition of the growth of | Retrospective study | 150 | untreated dyspeptic patients | No | Lower |
|
| Salem et al. (2010/ Saudi Arabia) ( | Anti-inflammatory/ Anticancer/ Antimicrobial activity/Inhibition of the growth of | Randomized, open, clinical trial | 88 | Nonulcer dyspeptic patients | Yes | Increased eradication rate/ Two g of |
|
| Alizadeh-Naini et al. (2020/ Iran) ( | Antioxidative/Anti-inflammatory effect of thymoquinone on NFκB | Randomized, double-blind, placebo-controlled, clinical trial | 51 | Patients with functional dyspepsia with positive | Yes | Significantly increasing the eradication rate/ A significant improvement in patients' quality of life/No differences in biochemical markers and dyspepsia between the two groups |
|
| Hashem-Dabaghian et al. (2016/Iran) ( | Pilot clinical trial | 19 | Positive | No | ||
|
| Gotteland et al. (2008/ Chile) ( | Probiotics have been proposed to produce organic acid and bacteriocins capable of inhibiting | Multicentric, randomized, double-blind, placebo-controlled, clinical trial | 295 | UBT-positive children | No | No synergism effects observed when simultaneously administering the cranberry juice and Lactobacillus /Temporary |
|
| Li et al. (2021/ China) ( | Proanthocyanidin for suppression of | Randomized, double-blind, placebo-controlled, clinical trial | 522 | Yes | Decreased viability of GC cell lines/Reduced esophageal adenocarcinoma/ | |
|
| Dabos et al. (2010 / Greece) ( | Medicinal product for gastrointestinal upsets with an acidic fraction that can kill | Randomized controlled clinical trial | 52 | A patient suffering from an | Yes | No effect of a combination of mastic gum and pantoprazole on |
|
| Castro et al. (2012/ Spain) ( | Antibacterial activity because of phenolic compounds | Pilot clinical trial | 1st study: 30; 2nd study: 30 | No | Moderate effectiveness in eradicating | |
|
| Momeni et al. (2014/ Iran) ( | Efficacious for | Randomized, double-blind, placebo-controlled, clinical trial | 60 | Patients with abdominal pain or dyspepsia and gastric ulcer, duodenal ulcer, gastritis or duodenitis in upper endoscopy and | Yes | As efficient as bismuth in |
|
| Hajiaghamohammadi et al. (2016/ Iran) ( | Antioxidant/Anti-cancer/Anti-inflammatory/ Secreting secretin/ Anti-adhesive effect against | Randomized controlled clinical trial | 120 | Patients suffering from dyspepsia either with peptic ulcer disease (PUD) or non-ulcer dyspepsia (NUD) with a positive rapid urease test | Yes | Higher eradication in patients with PUD/No difference in patients with dyspepsia |
|
| Mcnulty et al. (2001/ UK) ( | Reduced risk of gastric cancer | Pilot clinical trial | 5 | Dyspeptic patients with positive serology for | No | No evidence of |
|
| Nir et al. (2000) ( | Inhibition of the growth of | Pilot, randomized, placebo-controlled, clinical trial | 23 | Patients with positive Campylo Bacter Urease Test (CUT) | No | Did not demonstrate a decline in the colonization rate |
|
| Imani et al. (2020/ Iran) ( | Anti-inflammatory/ Antimicrobial activity | Randomized, double-blind, placebo-controlled, clinical trial | 98 | Yes | Increased eradication rate/Reduced complications of | |
|
| Coelho et al. (2007/ Brazil) ( | Phenolic components inhibiting | Pilot clinical trial | 18 | Positive UBT patients | No | No effect on the eradication rate in 83 percent of the patients |
|
| Shidfar et al. (2012/ Iran) ( | Interfering oxidative processes | Parallel group quasi-control trial | 54 | Patients had been referred to the endoscopy with a positive rapid urease test | Yes | No significant effect on the eradication rate |
|
| Celinski et al. / 2012/ Poland) ( | Potent endogenous antioxidants/Acting as a common mediator of inter-organ communication between the upper and lower portions of the gut | Randomized, placebo-controlled, clinical trial | 42 | Yes | Significant effect on the eradication rate (when added to omeprazole treatment) | |
|
| Abdi et al. (2018/ Iran) ( | Patient healing lesions like stomatitis, Oesophagitis, Peptic ulcers/ Cytoprotection/ Antioxidant/Free radical scavenger activity | Randomized, double-blind, placebo-controlled, clinical trial | 118 | Patients with positive rapid urease test via an endoscopy | Yes | No significant effect on the eradication rate in ITT or PP analysis |
|
| Campanale et al. (2014/ Italy) ( | Activating Urease and Hydrogenase | Pilot, randomized, controlled, clinical trial | 52 | Patients who had been diagnosed with | Yes | Increased eradication rate |
|
| Duggan et al. (1997/ England) ( | PUFAs inhibiting gastric acid secretion while increasing cytoprotective prostaglandins | Randomized, double-blind, placebo-controlled, clinical trial | 40 | Patients with proven infection with | Yes | No significant change in either the severity of |
|
| Frieri et al. (2000/ Italy) ( | Inhibiting the growth of | Blinded clinical trial | 15 | Yes | No effect on eradication; Modification of cellular membranes of both bacterium and host; Reduced |